Comparison of Effects of Pitavastatin and Rosuvastatin on Patients With Chronic Heart Failure

Comparison of Effects of Pitavastatin and Rosuvastatin on Patients With Chronic Heart Failure - effects of pitavastatin on chronic heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007695

Enrollment

Registered

2012-04-10

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

treatment with pitavastatin treatment withrosuvastatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: New York Heart Association (NYHA) functional class II or III and a diagnosis as hypercholesterolemia

Exclusion criteria

Exclusion criteria: receiving treatment with a statin; taking a coenzyme Q10 (CoQ10) prior to the randomization and history of cardiac events. The ethics committee at Chiba University Graduate School of Medicine approved the OPAL protocol, which adhered according to the principles of the Helsinki Declaration

Design outcomes

Primary

Measure	Time frame
serum LDL-cholesterol, total CoQ10 and the following biomarkers; markers of inflammation (high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha ) and pentraxin 3 (PTX3)), marker of the severity of heart failure (N-terminal pro-brain natriuretic peptide (NT-proBNP), tenascin C, and high-sensitivity cardiac troponin T (hs-TnT)), a marker of oxidative stress (urinary 8-isoprostane) and a marker of chronic kidney disease (urinary albumin to creatinine ratio (UACR)) at 12 weeks	—

Measure

Time frame

serum LDL-cholesterol, total CoQ10 and the following biomarkers; markers of inflammation (high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha ) and pentraxin 3 (PTX3)), marker of the severity of heart failure (N-terminal pro-brain natriuretic peptide (NT-proBNP), tenascin C, and high-sensitivity cardiac troponin T (hs-TnT)), a marker of oxidative stress (urinary 8-isoprostane) and a marker of chronic kidney disease (urinary albumin to creatinine ratio (UACR)) at 12 weeks

—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026